Black Diamond Therapeutics Inc (BDTX) - Total Assets
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) holds total assets worth $157.73 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BDTX net assets for net asset value and shareholders' equity analysis.
Black Diamond Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Black Diamond Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Black Diamond Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Black Diamond Therapeutics Inc's total assets of $157.73 Million consist of 82.5% current assets and 17.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Black Diamond Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Black Diamond Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Black Diamond Therapeutics Inc's current assets represent 82.5% of total assets in 2024, a decrease from 98.7% in 2017.
- Cash Position: Cash and equivalents constituted 29.7% of total assets in 2024, down from 98.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Black Diamond Therapeutics Inc Competitors by Total Assets
Key competitors of Black Diamond Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Black Diamond Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.94 | 5.55 | 22.48 |
| Quick Ratio | 8.94 | 5.55 | 22.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $123.45 Million | $94.74 Million | $305.34 Million |
Black Diamond Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Black Diamond Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.99 |
| Asset Growth Rate (YoY) | -22.7% |
| Total Assets | $122.64 Million |
| Market Capitalization | $121.36 Million USD |
Valuation Analysis
Near Book Valuation: The market values Black Diamond Therapeutics Inc's assets close to their book value (0.99x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Black Diamond Therapeutics Inc's assets decreased by 22.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Black Diamond Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Black Diamond Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $122.64 Million | -22.66% |
| 2023-12-31 | $158.57 Million | +1.48% |
| 2022-12-31 | $156.25 Million | -36.91% |
| 2021-12-31 | $247.68 Million | -24.87% |
| 2020-12-31 | $329.67 Million | +108.26% |
| 2019-12-31 | $158.29 Million | +205.44% |
| 2018-12-31 | $51.83 Million | +546.13% |
| 2017-12-31 | $8.02 Million | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant n… Read more